Rituximab in the treatment of rheumatoid arthritis

Expert Review of Clinical Immunology

Volumn 3, Issue 1, 2007, Pages 17-26

  Taylor, Peter C ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXORUBICIN; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ANTIBODY; VINCRISTINE SULFATE;

ANTIGEN PRESENTATION; APOPTOSIS; B LYMPHOCYTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; FLUSHING; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; HYPOTENSION; INFECTION; LYMPHOCYTE DEPLETION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; OPPORTUNISTIC INFECTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RELAPSE; RESPIRATORY TRACT INFECTION; RETREATMENT; REVIEW; RHEUMATOID ARTHRITIS; RIGOR; SIDE EFFECT; T LYMPHOCYTE; TREATMENT DURATION; TUBERCULOSIS;

EID: 33947273048     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.1.17     Document Type: Review

References (47)

1. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, Trang L. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow up of a prospective double blind placebo controlled study. J. Rheumatol. 22(12), 2208-2213 (1995).
2. van der Heide A, Jacobs JW, Bijlsma JW et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann. Intern. Med. 124(8), 699-707 (1996).
3. Lard LR, Visser H, Speyer I et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. Am. J. Med. 111(6), 446-51 (2001).
4. van Aken J, Lard LR, le Cessie S, Hazes JM, Breedveld FC, Huizinga TW. Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis. Ann. Rheum. Dis. 63(3), 274-279 (2004).
5. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined stepdown prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074), 309-318(1997).
6. Mottonen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet. 353(9164), 1568-1573 (1999).
7. Puolakka K, Kautiainen H, Mottonen T et al. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial. Arthritis Rheum. 52(1), 36-41 (2005).
8. Grigor C, Capell H, Stirling A et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430), 263-269 (2004).
9. Breedveld FC, P Emery, E Keystone et al. Ann. Rheum. Dis. 63(2), 149-155 (2004).
10. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26-37 (2006).
11. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343(22), 1586-1593 (2000).
12. Genovese MC, Bathon JM, Martin RW et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46(6), 1443-1450 (2002).
13. St Clair EW, van der Heijde DM, Smolen JS et al. Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50(11), 3432-3443 (2004).
14. Taylor PC, Steuer A, Gruber J et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum. 50(4), 1107-1116 (2004).
15. Taylor PC, Steuer A, Gruber J et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum. 54(1), 47-53 (2006).
16. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52(11), 3381-3390 (2005).
17. Quinn MA, Conaghan PG, O'Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52(1), 27-35 (2005).
18. Bohnhorst JO, Bjorgan MB, Thoen JE, Natvig JB, Thompson KM. Bm1-Bm5 classification of peripheral blood B cells reveals circulating germinal center founder cells in healthy individuals and disturbance in the B cell subpopulations in patients with primary Sjogren's syndrome. J. Immunol. 167(7), 3610-3618 (2001).
19. Koopman G, Keehnen RM, Lindhout E et al. Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J. Immunol. 152(8), 3760-3767 (1994).
20. Mackay F, Sierro F, Grey ST, Gordon TP. The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr. Dir. Autoimmun. 8, 243-65 (2005).
21. Bhatia A, Blades S, Cambridge G, Edwards JC. Differential distribution of FcγRIIIa in normal human tissues and colocalisation with DAF and fibrillin-1: implications for immunological microenvironments. Immunology 94(1), 56-63 (1998).
22. Abrahams VM, Cambridge G, Edwards JC. Induction of tumour necrosis factor a by human monocytes: a key role for FcγRIIIa in rheumatoid arthritis. Arthritis Rheum. 43(2), 608-616 (2002).
23. Edwards JCW and Cambridge G. B cell targeting in rheumatoid arthritis and other diseases. Nat. Rev. Immunol. 6(5), 394-405 (2006).
24. Riley JK, Sliwkoski MX. CD20: a gene in search of a function. Semin. Oncol. 27(6 Suppl 12), 17-24 (2000).
25. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene dist disruption. Immunogenetics 48(2), 125-132 (1998).
26. Szodoray P, Alex P, Dandapani V et al. Apoptotic effect of rituximab on peripheral B cells in RA. Scand. J. Immunol. 60(1-2), 209-218 (2004).
27. Tsokos GC. B cells, be gone - B-cell depletion in the treatment of rheumatoid arthritis. N. Engl. J. Med. 350(25), 2546-2548 (2004).
28. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40(2), 205-211 (2001).
29. De Vita S, Zaja F, Sacco S et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 46(8), 2029-2033 (2002).
30. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum. Dis. 61(10), 883-888 (2002).
31. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572-2581 (2004).
32. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. for the DANCER study group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a Phase IIB randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 54(5), 1390-1400 (2006).
33. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54(2) 793 (2006).
34. Cohen S, Emery P, Greenwald M et al. Prolonged efficacy of rituximab in rheumatoid arthritis patients with inadequate response to one or more tnf inhibitors: 1-year follow-up of a subset of patients receiving a single course in a controlled trial (reflex study) Ann Rheum. Dis. 65(Suppl II), 183 (2006).
35. Keystone E, Emery P, Peterfy CG et al. Prevention of joint structural damage at 1 year in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX). Ann. Rheum. Dis. 65(Suppl II), 58 (2006).
36. Morbacher A. B cell non-Hodgkin's lymphoma: rituximab safety experience. Arthritis Res. Ther. 7(Suppl 3), S19-S25 (2005).
37. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J. Clin. Oncol. 16(8), 2825-2833 (1998).
38. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single agent pivotal trial. Semin. Oncol. 26(5 Suppl 14), 79-87 (1999).
39. Coffier B, Lepage E, Brier J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N. Engl. J. Med. 346(4), 235-242 (2002).
40. Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying anti-rheumatic drugs and anti-TNFα treatment. J. Rheumatol. 32(11), 2109-2115 (2005).
41. Emery P, Fleischman RM, Filipowicz-Sosnowska A et al. Rituximab in rheumatoid arthritis: a double-blind, placebo-controlled, dose ranging study. Arthritis Rheum. 52(Suppl.), S709 (2005).
42. Cambridge G, Leandro MJ, Edwards JC et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48(8), 2146-2154 (2003).
43. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstiution of peripheral blood B cells following rituximab treatment with in patients with rheumatoid arthritis Arthritis Rheum. 54(2), 613-620 (2006).
44. Cambridge G, Stohl W, Leandro MJ, Migone T-S, Hilbert DM, Edwards JC. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment. Relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54(3), 723-732 (2006).
45. van Vollenhoven RF, Cohen S , Pavelka K et al. Response to rituximab in patients with rheumatoid arthritis is maintained by repeat therapy: results of an open-label trial. Ann Rheum. Dis. 65(Suppl II), 510 (2006).
46. Scheinberg M, Hamerschlak N, Kutner JM, Ribeiro AA, Ferreira E, Goldenberg J, Kiss MH, Chahade WH. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). Clin. Exp. Rheumatol. 24(652006
47. McKay J, Chwalinska-Sadowska H, Boling E et al. 'Efficacy and safety of belimumab (BMAB), a fully human monoclonal antibody to B lymphocyte stimulator (BLyS) for the treatment of rheumatoid arthritis'. Arthritis Rheum. 52(Suppl.), S710 (2005).